GOVX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

GO

Volume

144.38K

Next Earnings

November 12th

Loading chart

GO

GOVXGeoVax Labs, Inc. New

GOVX

Pay with—

Available Balance0.00

GO

Mkt Cap

$2.3M

Volume

144.38K

Next Earnings

November 12th

Chart Financials Earnings News About Insider Filings

Is Co-Diagnostics National Security’s Next Diagnostic Pick?Following the WHO's declaration of a Public Health Emergency for the Bundibugyo virus Ebola outbreak on May 17, 2026, biodefense diagnostics companies are experiencing significant capital inflows. Co-Diagnostics is positioned as a strategic play due to its decentralized manufacturing network through joint ventures in India (CoSara) and Saudi Arabia (CoMira), which addresses national security demands for localized production. The company is advancing PCR assays for Ebola detection and has near-term catalysts including FDA 510(k) submission and India TB test commercialization in Q3 2026, though the stock's recent 200%+ surge on low float presents both opportunity and volatility.Investing.com · May 28, 2026

WHO Africa Chief Warns It's A 'Big Mistake' To Underestimate Ebola Outbreak As Deadly Virus Spreads Beyond CongoThe WHO Africa regional director Mohamed Yakub Janabi warned against underestimating the Ebola outbreak in the Democratic Republic of Congo, which has reported 670 suspected cases and 61 confirmed infections. The Bundibugyo strain has no approved vaccine and has already spread to Uganda. Containment efforts are hampered by population movement, misinformation, and community mistrust. Former CDC Director Robert Redfield warned the outbreak could become a significant pandemic.Benzinga · May 23, 2026

GeoVax Stock Higher As Company Highlights MVA Platform For Ebola ThreatsGeoVax Labs (GOVX) shares surged 16.42% to $2.34 as the company highlighted its MVA vaccine platform's potential to address emerging Ebola and hemorrhagic fever threats, following a WHO emergency declaration. The company announced a $3 million private placement and plans Phase 3 testing of its mpox and smallpox vaccine candidate in Q4 2026. Despite the rally, the stock remains down 91% over the past 12 months.Benzinga · May 20, 2026

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research PrioritiesSeveral biotech companies are advancing cancer research with promising clinical milestones, focusing on innovative immunotherapies and targeted treatments amid rising cancer incidence and potential research funding challenges.Benzinga · Jul 16, 2025

Presenting on Emerging Growth Conference 84 Day 2 on July 17; Register to live streamEmergingGrowth.com announced the schedule for its 84th conference featuring presentations from multiple public companies across technology, biotech, and other sectors on July 16-17, 2025.GlobeNewswire Inc. · Jul 16, 2025

Presenting on the Emerging Growth Conference 78 Day 2 on January 16 Register NowEmergingGrowth.com announces the schedule for the 78th Emerging Growth Conference, featuring presentations from various companies across different growth sectors.GlobeNewswire Inc. · Jan 15, 2025

GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity ConferenceGeoVax Labs, a biotechnology company, announced that its CEO will present at the NobleCon20 conference. The company is developing COVID-19 vaccines and cancer immunotherapies, with its lead clinical programs being GEO-CM04S1 and Gedeptin.GlobeNewswire Inc. · Nov 26, 2024

GeoVax Reports Third Quarter 2024 Financial Results and Provides Business UpdateGeoVax Labs announced progress in its COVID-19 vaccine trials, including the BARDA/Project NextGen Phase 2b trial and upcoming data readouts from existing Phase 2 trials. The company also provided updates on its Gedeptin and GEO-MVA Mpox vaccine programs.GlobeNewswire Inc. · Nov 12, 2024

GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024GeoVax, a biotechnology company, will report its third quarter 2024 financial results and provide a corporate update on November 12, 2024. The company will host a conference call and webcast to discuss the results and provide an update on its clinical programs.GlobeNewswire Inc. · Nov 5, 2024

GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities ConferenceGeoVax Labs, a biotechnology company, announced that its Chairman & CEO, David Dodd, will participate in a panel discussion on innovative therapies for solid tumors at the 3rd Annual ROTH Healthcare Opportunities Conference.GlobeNewswire Inc. · Oct 2, 2024

to start trading

GO

GOVXGeoVax Labs, Inc. New

GOVX

Pay with—

Available Balance0.00

Your PositionYou don't own any GOVX yet.

Related Tickers

Earnings